Q2 STOCKS TO BUY

Johnson & Johnson Stock Dips on Asbestos Cancer Verdict

Jefferies responded with a price-target cut for JNJ

Managing Editor
Jul 13, 2018 at 10:10 AM
facebook X logo linkedin


Shares of Johnson & Johnson (NYSE:JNJ) are lower in early trading, as investors digest the verdict of a St. Louis trial that concluded that asbestos in the company's talc-based products caused ovarian cancer in 22 women. The jury ordered Johnson & Johnson to pay $4.7 billion in damages. Shares of the Dow stock are down 0.7% at $126.89, at last check.

In response, Jefferies slashed its price target to $145 on JNJ, but maintained its "buy" rating. Analysts in general are split on the stock, with exactly 50% of the 18 firms covering the stock already offering tepid "hold" or "sell" ratings. However, the stock's average 12-month price target of $142.24 still stands at a premium to current levels.

Earlier this month, Johnson & Johnson stock broke north of a channel of lower highs and lows that had contained the shares since the early February correction. The stock has added 4.8% so far in July, set for its best month since October. Year-to-date, however, JNJ shares are still down roughly 9%.

Ahead of the verdict, options traders were increasingly bullish. This is evident per Johnson & Johnson stock's 10-day call/put volume ratio of 3.01 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) -- ranking in the 94th annual percentile. This indicates that calls have been purchased over puts at a faster-than-usual clip during the past two weeks.

Digging deeper, the expiring weekly 7/13 126-strike call saw the largest increase in open interest during the past 10 days, followed by the July 128 call -- the latter of which encompasses the company's earnings release, set for July 17. Echoing this, JNJ's Schaeffer's put/call open interest ratio (SOIR) sits at 0.85 and ranks in the 36th percentile of its annual range, indicating calls handily outnumber puts among options set to expire within three months.

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter